Breelyn A Wilky

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/38524/publications.pdf

Version: 2024-02-01

47 papers	1,428 citations	394421 19 h-index	361022 35 g-index
48 all docs	48 docs citations	48 times ranked	2605 citing authors

#	Article	IF	Citations
1	Emerging mechanisms of immunotherapy resistance in sarcomas. Cancer Drug Resistance (Alhambra,) Tj ETQq1 1 0.784314 rgBT /Ov	2.1	1
2	Sounding the Alarm on Leiomyosarcoma Recurrence: Role of Circulating Tumor DNA. Clinical Cancer Research, 2022, , .	7.0	0
3	Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations inCTNNB1orAPC: A Multi-institutional Retrospective Study. Clinical Cancer Research, 2022, 28, 4092-4104.	7.0	8
4	Immunotherapy in Sarcoma. Surgical Oncology Clinics of North America, 2022, 31, 381-397.	1.5	9
5	Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patientsâ€"A Position Paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN). Cancers, 2021, 13, 886.	3.7	17
6	Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction. Annals of Translational Medicine, 2021, 9, 1035-1035.	1.7	9
7	Current Management of Angiosarcoma: Recent Advances and Lessons From the Past. Current Treatment Options in Oncology, 2021, 22, 61.	3.0	21
8	MRI Volumetrics and Image Texture Analysis in Assessing Systemic Treatment Response in Extra-Abdominal Desmoid Fibromatosis. Radiology Imaging Cancer, 2021, 3, e210016.	1.6	7
9	High grade sarcoma presenting as multifocal recurrent seromas after inguinal hernia repair: A case report. Rare Tumors, 2020, 12, 203636132097574.	0.6	2
10	Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth. Cancers, 2020, 12, 141.	3.7	17
11	Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. , 2019, 7, 213.		118
12	Immune checkpoint inhibitors: The linchpins of modern immunotherapy. Immunological Reviews, 2019, 290, 6-23.	6.0	150
13	Future directions in soft tissue sarcoma treatment. Current Problems in Cancer, 2019, 43, 300-307.	2.0	17
14	Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. Lancet Oncology, The, 2019, 20, 837-848.	10.7	262
15	Pericytoma With t(7;12) and ACTB-GLI1 Fusion. American Journal of Surgical Pathology, 2019, 43, 1682-1692.	3.7	45
16	Precision medicine in gastrointestinal stromal tumors. Discovery Medicine, 2019, 28, 267-276.	0.5	6
17	Malignant progression of a peripheral nerve sheath tumor in the setting of rhabdoid tumor predisposition syndrome. Pediatric Blood and Cancer, 2018, 65, e27030.	1.5	3
18	The current landscape of early drug development for patients with sarcoma in the immunotherapy era. Future Oncology, 2018, 14, 1197-1211.	2.4	11

#	Article	IF	Citations
19	Current and Future Directions for Angiosarcoma Therapy. Current Treatment Options in Oncology, 2018, 19, 14.	3.0	75
20	A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas. Clinical Sarcoma Research, 2018, 8, 21.	2.3	22
21	Local recurrence of soft-tissue sarcoma: issues in imaging surveillance strategy. Skeletal Radiology, 2018, 47, 1595-1606.	2.0	34
22	Myoepithelial carcinoma or epithelioid sarcoma â€“ A rare diagnosis with poor prognosis. A case report and review of literature. International Journal of Surgery Case Reports, 2018, 49, 239-243.	0.6	3
23	Limbâ€sparing surgery plus radiotherapy results in superior survival: an analysis of patients with highâ€grade, extremity softâ€tissue sarcoma from the <scp>NCDB</scp> and <scp>SEER</scp>. Cancer Medicine, 2018, 7, 4228-4239.	2.8	23
24	A nonrandom association of sarcoidosis in patients with gastrointestinal stromal tumor and other sarcomas. Rare Tumors, 2018, 10, 203636131878762.	0.6	3
25	Phase I open-label, ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies: Dose selection for combination with PD-1 blockade.. Journal of Clinical Oncology, 2018, 36, 3075-3075.	1.6	2
26	Growing Pains: a Simulation-Based Curriculum for Improving the Transition to Hematology/Oncology Fellowship. Journal of Cancer Education, 2017, 32, 496-502.	1.3	7
27	Current status of immunotherapy for gastrointestinal stromal tumor. Cancer Gene Therapy, 2017, 24, 130-133.	4.6	40
28	Latest advances in adult gastrointestinal stromal tumors. Future Oncology, 2017, 13, 2183-2193.	2.4	7
29	A pilot study of NY-ESO-1c259 T cells in subjects with advanced myxoid/round cell liposarcoma (NCT02992743).. Journal of Clinical Oncology, 2017, 35, TPS3097-TPS3097.	1.6	1
30	The Current Landscape of Early Drug Development for Patients With Sarcoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 807-810.	3.8	3
31	Desmoid fibromatosis: MRI features of response to systemic therapy. Skeletal Radiology, 2016, 45, 1365-1373.	2.0	46
32	RNA helicase DDX3: a novel therapeutic target in Ewing sarcoma. Oncogene, 2016, 35, 2574-2583.	5.9	49
33	Panobinostat and carfilzomib cytotoxicity in IDH-mutant human chondrosarcoma.. Journal of Clinical Oncology, 2016, 34, 11027-11027.	1.6	0
34	Value added. Current Opinion in Oncology, 2015, 27, 323-331.	2.4	27
35	The Biology and Management of Cartilaginous Tumors: A Role For Targeting Isocitrate Dehydrogenase. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e648-e655.	3.8	13
36	Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells. PLoS ONE, 2015, 10, e0133813.	2.5	88

#	Article	IF	Citations
37	A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours. British Journal of Cancer, 2015, 112, 24-31.	6.4	35
38	RNA helicase DDX3 is a novel therapeutic target for Ewing sarcoma.. Journal of Clinical Oncology, 2015, 33, 10026-10026.	1.6	1
39	A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas.. Journal of Clinical Oncology, 2015, 33, 10560-10560.	1.6	1
40	Cell-Cycle Dependent Expression of a Translocation-Mediated Fusion Oncogene Mediates Checkpoint Adaptation in Rhabdomyosarcoma. PLoS Genetics, 2014, 10, e1004107.	3.5	38
41	Immunotherapy in sarcoma: a new frontier. Discovery Medicine, 2014, 17, 201-6.	0.5	12
42	Extrathoracic Location and â€œBorderlineâ€•Histology are Associated with Recurrence of Solitary Fibrous Tumors After Surgical Resection. Annals of Surgical Oncology, 2013, 20, 4080-4089.	1.5	53
43	A doseâ€finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma. International Journal of Cancer, 2013, 133, 997-1005.	5.1	39
44	LGR5 is Expressed by Ewing Sarcoma and Potentiates Wnt/Î²-Catenin Signaling. Frontiers in Oncology, 2013, 3, 81.	2.8	41
45	Pazopanib in sarcomas. Current Opinion in Oncology, 2013, 25, 373-378.	2.4	20
46	A Novel Chordoma Xenograft Allows In Vivo Drug Testing and Reveals the Importance of NF-Î¹B Signaling in Chordoma Biology. PLoS ONE, 2013, 8, e79950.	2.5	23
47	Beyond Palliation: Therapeutic Applications Of 153Samarium-EDTMP. Clinical & Experimental Pharmacology, 2013, 03, .	0.3	12